Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4 Hydroxybutyrate Sodium
2. 4-hydroxybutyrate Sodium
3. Gamma Hydroxybutyrate
4. Gamma-hydroxybutyrate
5. Oxybate Sodium
6. Oxybate, Sodium
7. Oxybutyrate, Sodium
8. Sodium Gamma Hydroxybutyrate
9. Sodium Gamma-hydroxybutyrate
10. Sodium Oxybutyrate
11. Somsanit
12. Xyrem
1. 502-85-2
2. Sodium 4-hydroxybutyrate
3. Anetamin
4. 4-hydroxybutyric Acid Sodium Salt
5. Sodium 4-hydroxybutanoate
6. Somsanit
7. Oxybate Sodium
8. Gamma Oh
9. Sodium Oxybate [usan]
10. Sodium Oxybutyrate
11. Catabate
12. Sodium Oxybat
13. Oxybate (sodium)
14. 4-hydroxybutyrate Sodium
15. Wy-3478
16. Butanoic Acid, 4-hydroxy-, Monosodium Salt
17. Gamma-hydroxybutyrate Sodium
18. Sodium Gamma-hydroxybutyrate
19. Sodium;4-hydroxybutanoate
20. Gamma-hydroxy Sodium Butyrate
21. Butanoic Acid, 4-hydroxy-, Sodium Salt
22. Eb 27
23. Hydroxybutyric Acid Monosodium Salt
24. 4-hydroxybutyric Acid Monosodium Salt
25. Wy 3478
26. .gamma.-hydroxybutyrate Sodium Salt
27. Nsc-84223
28. Sodium Oxybate (usan)
29. 7g33012534
30. Butyric Acid, 4-hydroxy-, Monosodium Salt
31. Butyric Acid, 4-hydroxy-, Sodium Salt
32. Natrium 4-hydroxybutyrat
33. Sodium-4-hydroxybutyrate
34. Sodium Oxybate (sodium 4-hydroxybutanoate)
35. Ghb Sodium Salt (sodium Gammahydroxybutyrate)
36. 4-hydroxybuttersaeure Natriumsalz
37. Gamma-hydroxybutyrate Sodium Salt
38. Ncgc00247714-01
39. Einecs 207-953-3
40. Nsc 84223
41. Gamma-hydroxybutyric Acid, Sodium Salt
42. Jzp-6
43. Sodium4-hydroxybutyrate
44. Acetamide,2,2-dichloro-n-[(1r,2r)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-,rel-
45. Unii-7g33012534
46. Xyrem (tn)
47. Sodium Gammahydroxybutyrate
48. Dsstox_cid_28866
49. Dsstox_rid_83135
50. Dsstox_gsid_48940
51. Schembl61823
52. Sodium Oxybate [hsdb]
53. Sodium Oxybate [vandf]
54. Dea No. 2012
55. Sodium Oxybate [mart.]
56. Chembl1200682
57. Dtxsid3048940
58. Oxybate Sodium [who-dd]
59. Sodium Oxybate [ema Epar]
60. Hms2091e15
61. Hy-b1187
62. Tox21_112871
63. Sodium Oxybate [orange Book]
64. Gamma Hydroxybutyric Acid Preparations
65. Xywav Component Sodium Oxybate
66. Akos006221428
67. Ccg-212465
68. Cs-4796
69. Db09072
70. Sodium Oxybate Component Of Xywav
71. Cas-502-85-2
72. Db-071156
73. Ft-0626615
74. D05866
75. H-4040
76. Sodium Salt Of Gamma-hydroxybutyric Acid
77. .gamma.-hydroxybutyrate Sodium Salt [mi]
78. Butanoic Acid, 4-hydroxy-, Sodium Salt (1:1)
79. Q7553347
80. 90318-49-3
Molecular Weight | 126.09 g/mol |
---|---|
Molecular Formula | C4H7NaO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 126.02928836 g/mol |
Monoisotopic Mass | 126.02928836 g/mol |
Topological Polar Surface Area | 60.4 Ų |
Heavy Atom Count | 8 |
Formal Charge | 0 |
Complexity | 64.3 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Xyrem |
PubMed Health | Sodium Oxybate (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Sodium oxybate, a CNS depressant, is the active ingredient in Xyrem. The chemical name for sodium oxybate is sodium 4-hydroxybutyrate. The molecular formula is C4H7NaO3, and the molecular weight is 126.09 g/mole. The chemical structure is:Sodium oxyb... |
Active Ingredient | Sodium oxybate |
Dosage Form | Solution |
Route | Oral |
Strength | 500mg/ml |
Market Status | Prescription |
Company | Jazz Pharms |
2 of 2 | |
---|---|
Drug Name | Xyrem |
PubMed Health | Sodium Oxybate (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | Sodium oxybate, a CNS depressant, is the active ingredient in Xyrem. The chemical name for sodium oxybate is sodium 4-hydroxybutyrate. The molecular formula is C4H7NaO3, and the molecular weight is 126.09 g/mole. The chemical structure is:Sodium oxyb... |
Active Ingredient | Sodium oxybate |
Dosage Form | Solution |
Route | Oral |
Strength | 500mg/ml |
Market Status | Prescription |
Company | Jazz Pharms |
For the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy.
FDA Label
Treatment of narcolepsy with cataplexy in adult patients.
Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended. ,
Sodium oxybate works through an unknown mechanism to treat narcolepsy by inducing sleep within about 5-15 minutes of administration.
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
Anesthetics, Intravenous
Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)
N07XX04
N07BB
B05XA02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N01 - Anesthetics
N01A - Anesthetics, general
N01AX - Other general anesthetics
N01AX11 - Sodium oxybate
N - Nervous system
N07 - Other nervous system drugs
N07X - Other nervous system drugs
N07XX - Other nervous system drugs
N07XX04 - Sodium oxybate
Absorption
Absolute bioavailability is approximately 88%. Tmax of 30.7-51.9min.
Route of Elimination
The major metabolite is carbon dioxide which is cleared by expiration, less then 5% appears as the unchanged drug in the urine within 6-8 hours after dosing.
Volume of Distribution
Vd of 37.7-67.7
Clearance
Total clearance of 895-1361mL/min.
Animal studies indicate that the major elimination pathway is metabolism by the creation of carbon dioxide and water through the Krebs cycle and secondarily by beta-oxidation. In the primary pathway hydroxyacid-oxoacid transhydrogenase catalyzes the conversion of sodium oxybate to succinic semialdehyde which is then transformed to succinic acid by succinic semmialdehyde dehydrogenase. Succinic acid is then turned into carbon dioxide and water in the Krebs cycle. Succinic semialdehyde is also metabolised into carbon dioxide and water by a transhydrofenase in the presence of alpha ketoglutarate.
0.5 to 1 hour.
The exact mechanism of action is unknown. It is the sodium salt of the endogenous compound gamma hydroxybutyrate which is a metabolite of the GABA neurotransmitter and it's thought that it's therapeutic effects are mediated via GABA B actions at noradrenergic, dopaminergic and thalamocortical neurons.
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-28
Pay. Date : 2012-12-19
DMF Number : 24049
Submission : 2010-08-02
Status : Active
Type : II
NDC Package Code : 49812-0207
Start Marketing Date : 2010-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2025-02-11
Valid Till : 2027-06-09
Written Confirmation Number : WC-0278
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-04-25
Pay. Date : 2022-02-28
DMF Number : 36577
Submission : 2022-02-18
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-05-31
Pay. Date : 2022-05-17
DMF Number : 35870
Submission : 2022-04-25
Status : Active
Type : II
NDC Package Code : 59116-5950
Start Marketing Date : 2021-12-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-28
Pay. Date : 2013-12-06
DMF Number : 27599
Submission : 2013-09-26
Status : Active
Type : II
NDC Package Code : 17180-2010
Start Marketing Date : 2002-07-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (13kg/13kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33094
Submission : 2018-09-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40348
Submission : 2025-02-28
Status : Active
Type : II
NDC Package Code : 61960-0221
Start Marketing Date : 2017-12-06
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-10-06
Pay. Date : 2022-08-17
DMF Number : 28289
Submission : 2014-06-19
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-06-05
Written Confirmation Number : WC-0370
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7249
Submission : 1987-12-11
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-04-25
Pay. Date : 2022-02-28
DMF Number : 36577
Submission : 2022-02-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-08-28
Pay. Date : 2012-12-19
DMF Number : 24049
Submission : 2010-08-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-10-06
Pay. Date : 2022-08-17
DMF Number : 28289
Submission : 2014-06-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7249
Submission : 1987-12-11
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-05-31
Pay. Date : 2022-05-17
DMF Number : 35870
Submission : 2022-04-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40348
Submission : 2025-02-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-28
Pay. Date : 2013-12-06
DMF Number : 27599
Submission : 2013-09-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3274
Submission : 1978-07-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33094
Submission : 2018-09-11
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Gamma-Hydroxybutyric Acid Sodium
About the Company : Founded in 1979, Noramco specializes in the development and manufacturing of APIs for both opioid and non-opioid products. With expertise in controlled substance development and ma...
About the Company : Rusan Pharma is a fully integrated global pharmaceutical company specializing in the treatment of addiction & pain management. We manufacture & market a wide range of APIs & formul...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...
About the Company : Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of...
About the Company : Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners tur...
About the Company : Farmak International is a leading GMP EU certified pharmaceutical manufacturer in Ukraine established in 1925 with FDA inspected site for production of food supplement. Company spe...
Gamma-Hydroxybutyric Acid Sodium
About the Company : OmnisMed Pharmaceuticals believes that good healthcare must be accessible to everyone; That is the core of our philosophy. We are experts in providing a wide range of high-quality ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Lumryz is an extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2024
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avadel Announces FDA Approval of LUMRYZ™ For Narcolepsy in Patients 7 And Older
Details : Lumryz is an extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2024
Details:
Lumryz is an investigational, extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of idiopathic hypersomnia.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2024
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avadel Announces First Patient Dosed in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia
Details : Lumryz is an investigational, extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of idiopathic hypersomnia.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2024
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Musculoskeletal Brand Name: Lumryz
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2023
Details:
The offering will be used for obtaining FDA approval of company's lead candidate, Lumryz, an investigational, extended-release formulation of sodium oxybate for the treatment of cataplexy or EDS in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 29, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $125.0 million
Deal Type : Public Offering
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
Details : The offering will be used for obtaining FDA approval of company's lead candidate, Lumryz, an investigational, extended-release formulation of sodium oxybate for the treatment of cataplexy or EDS in adults with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 29, 2023
Details:
The financing will support the potential commercialization of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: RTW Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 29, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : RTW Investments
Deal Size : $75.0 million
Deal Type : Agreement
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
Details : The financing will support the potential commercialization of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 29, 2023
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2023
Details:
sodium oxybate oral solution indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Musculoskeletal Brand Name: Xyrem-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : sodium oxybate oral solution indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Product Name : Xyrem-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2023
Details:
Lumryz (sodium oxybate) is a sodium salt of GHB, a naturally occurring CNS depressant that increases dopamine levels and increases serotonin turnover. It is being developed for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Musculoskeletal Brand Name: Lumryz
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) Extended Release...
Details : Lumryz (sodium oxybate) is a sodium salt of GHB, a naturally occurring CNS depressant that increases dopamine levels and increases serotonin turnover. It is being developed for the treatment of cataplexy or excessive daytime sleepiness in adults with nar...
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2023
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2023
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Musculoskeletal Brand Name: Lumryz
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Rel...
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Product Name : Lumryz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2023
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2037-07-21
US Patent Number : 12097175
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 214755
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-07-21
Patent Expiration Date : 2037-07-21
US Patent Number : 12109186
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 214755
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-07-21
Patent Expiration Date : 2037-07-21
US Patent Number : 12115145
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 214755
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-07-21
Patent Expiration Date : 2037-07-21
US Patent Number : 12115143
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 214755
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-07-21
Patent Expiration Date : 2037-07-21
US Patent Number : 12226377
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 214755
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-07-21
Patent Expiration Date : 2037-07-21
US Patent Number : 11400065
Drug Substance Claim :
Drug Product Claim :
Application Number : 214755
Patent Use Code : U-3579
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-07-21
Patent Expiration Date : 2033-09-15
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE
US Patent Number : 10864181*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 212690
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-09-15
Patent Expiration Date : 2033-03-15
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE
US Patent Number : 11986446
Drug Substance Claim :
Drug Product Claim :
Application Number : 212690
Patent Use Code : U-3017
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-03-15
Patent Expiration Date : 2033-01-11
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE
US Patent Number : 8591922
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212690
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-01-11
Patent Expiration Date : 2033-03-15
US Patent Number : 9486426
Drug Substance Claim :
Drug Product Claim :
Application Number : 21196
Patent Use Code : U-1532
Delist Requested :
Patent Use Description : METHOD OF TREATING EXC...
Patent Expiration Date : 2033-03-15
ABOUT THIS PAGE
65
PharmaCompass offers a list of Gamma-Hydroxybutyric Acid Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gamma-Hydroxybutyric Acid Sodium manufacturer or Gamma-Hydroxybutyric Acid Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gamma-Hydroxybutyric Acid Sodium manufacturer or Gamma-Hydroxybutyric Acid Sodium supplier.
PharmaCompass also assists you with knowing the Gamma-Hydroxybutyric Acid Sodium API Price utilized in the formulation of products. Gamma-Hydroxybutyric Acid Sodium API Price is not always fixed or binding as the Gamma-Hydroxybutyric Acid Sodium Price is obtained through a variety of data sources. The Gamma-Hydroxybutyric Acid Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sodium Oxybate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sodium Oxybate, including repackagers and relabelers. The FDA regulates Sodium Oxybate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sodium Oxybate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sodium Oxybate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sodium Oxybate supplier is an individual or a company that provides Sodium Oxybate active pharmaceutical ingredient (API) or Sodium Oxybate finished formulations upon request. The Sodium Oxybate suppliers may include Sodium Oxybate API manufacturers, exporters, distributors and traders.
click here to find a list of Sodium Oxybate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sodium Oxybate DMF (Drug Master File) is a document detailing the whole manufacturing process of Sodium Oxybate active pharmaceutical ingredient (API) in detail. Different forms of Sodium Oxybate DMFs exist exist since differing nations have different regulations, such as Sodium Oxybate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sodium Oxybate DMF submitted to regulatory agencies in the US is known as a USDMF. Sodium Oxybate USDMF includes data on Sodium Oxybate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sodium Oxybate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sodium Oxybate suppliers with USDMF on PharmaCompass.
A Sodium Oxybate written confirmation (Sodium Oxybate WC) is an official document issued by a regulatory agency to a Sodium Oxybate manufacturer, verifying that the manufacturing facility of a Sodium Oxybate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sodium Oxybate APIs or Sodium Oxybate finished pharmaceutical products to another nation, regulatory agencies frequently require a Sodium Oxybate WC (written confirmation) as part of the regulatory process.
click here to find a list of Sodium Oxybate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sodium Oxybate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sodium Oxybate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sodium Oxybate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sodium Oxybate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sodium Oxybate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sodium Oxybate suppliers with NDC on PharmaCompass.
Sodium Oxybate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sodium Oxybate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sodium Oxybate GMP manufacturer or Sodium Oxybate GMP API supplier for your needs.
A Sodium Oxybate CoA (Certificate of Analysis) is a formal document that attests to Sodium Oxybate's compliance with Sodium Oxybate specifications and serves as a tool for batch-level quality control.
Sodium Oxybate CoA mostly includes findings from lab analyses of a specific batch. For each Sodium Oxybate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sodium Oxybate may be tested according to a variety of international standards, such as European Pharmacopoeia (Sodium Oxybate EP), Sodium Oxybate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sodium Oxybate USP).